We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
226
CALL
DELISTED
bluebird bio
BLUE
– –
-8,199
Closed -$3.2M
BLUE
227
DELISTED
bluebird bio
BLUE
– –
-22
Closed -$8K
BPMC
228
PUT
DELISTED
Blueprint Medicines
BPMC
– –
-120,000
Closed -$11.7M
BTAI icon
229
CALL
BioXcel Therapeutics
BTAI
$24.5M
– –
-9,375
Closed -$6.47M
BTAI icon
230
BioXcel Therapeutics
BTAI
$24.5M
– –
-327
Closed -$226K
CGEN icon
231
PUT
Compugen
CGEN
$220M
– –
-500
Closed -$4K
CLOV icon
232
CALL
Clover Health Investments
CLOV
$2.29B
– –
-250,000
Closed -$1.89M
CLOV icon
233
Clover Health Investments
CLOV
$2.29B
– –
-100,000
Closed -$757K
CRDF icon
234
PUT
Cardiff Oncology
CRDF
$66.2M
– –
-417,900
Closed -$3.87M
CRIS icon
235
CALL
Curis
CRIS
$9.67M
– –
-250
Closed -$1.13M
CRIS icon
236
Curis
CRIS
$9.67M
– –
-3,051
Closed -$13.8M
CVAC
237
CALL
DELISTED
CureVac
CVAC
– –
-100,000
Closed -$9.14M
CVAC
238
PUT
DELISTED
CureVac
CVAC
– –
-360,000
Closed -$32.9M
CYRX icon
239
CryoPort
CYRX
$773M
– –
-2,900
Closed -$151K
EPIX
240
DELISTED
ESSA Pharma
EPIX
– –
-264,868
Closed -$7.69M
EXAS
241
PUT
DELISTED
Exact Sciences
EXAS
– –
-205,000
Closed -$27M
GOSS icon
242
CALL
Gossamer Bio
GOSS
$87.2M
– –
-300,000
Closed -$2.77M
IBB icon
243
CALL
iShares Biotechnology ETF
IBB
$9.52B
– –
-250,000
Closed -$37.6M
IGMS
244
DELISTED
IGM Biosciences
IGMS
– –
-300
Closed -$23K
IGMS
245
PUT
DELISTED
IGM Biosciences
IGMS
– –
-250,000
Closed -$19.2M
IONS icon
246
CALL
Ionis Pharmaceuticals
IONS
$8.85B
– –
-90,000
Closed -$4.05M
IWM icon
247
PUT
iShares Russell 2000 ETF
IWM
$80.2B
– –
-450,000
Closed -$99.4M
JAZZ icon
248
CALL
Jazz Pharmaceuticals
JAZZ
$16.2B
– –
-100,000
Closed -$16.4M
KNSA icon
249
Kiniksa Pharmaceuticals
KNSA
$6.1B
– –
-51,273
Closed -$949K
KPTI icon
250
Karyopharm Therapeutics
KPTI
$159M
– –
-53
Closed -$9K
8 9
10
11 12

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.